VACCBarinthus Biotherapeutics Plc.


$ 2.60 $ 0.07 (2.93 %)    

Wednesday, 24-Apr-2024 14:39:21 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.5
$ 2.60
$ 2.44 x 200
$ 0.00 x 0
$ 2.60 - $ 2.60
$ 1.64 - $ 5.10
6,864
na
na
$ 0.58
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaccitech-renames-as-barinthus-biotherapeutics-to-highlight-strategic-evolution-into-a-t-cell-immunotherapy-company-targeting-chronic-infectious-diseases-autoimmunity-and-cancer-to-trade-under-new-name-and-ticker-brns-effective-nov-7

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data

 vaccitech-shares-resume-trade
Vaccitech Shares Resume Trade
09/25/2023 16:36:53

 alliance-global-partners-initiates-coverage-on-vaccitech-with-buy-rating-announces-price-target-of-12

Alliance Global Partners analyst James Molloy initiates coverage on Vaccitech (NASDAQ:VACC) with a Buy rating and announces ...

 morgan-stanley-downgrades-vaccitech-to-equal-weight-lowers-price-target-to-325

Morgan Stanley analyst Matthew Harrison downgrades Vaccitech (NASDAQ:VACC) from Overweight to Equal-Weight and lowers the pr...

 stocks-that-hit-52-week-lows-on-monday

  Monday's session saw 175 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  On Thursday, 283 companies set new 52-week lows.

 morgan-stanley-maintains-overweight-on-vaccitech-lowers-price-target-to-14

Morgan Stanley analyst Matthew Harrison maintains Vaccitech (NASDAQ:VACC) with a Overweight and lowers the price target from...

 vaccitech-q2-eps-062-misses-055-estimate-sales-33400k-miss-60000k-estimate

Vaccitech (NASDAQ:VACC) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.55) b...

 vaccitech-to-present-final-data-at-easl-congress-for-phase-1b2-hbv002-study-in-adults-with-chronic-hepatitis-b

Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a ...

Core News & Articles

The objective of the additional treatment arm is to assess if a low dose of nivolumab, in combination with the booster dose(s) ...

 hc-wainwright--co-reiterates-buy-on-vaccitech-maintains-15-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vaccitech (NASDAQ:VACC) with a Buy and maintains $15 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION